Search
Clinician Ordering Portal
Scientific evidence
An objective fully automated Barrett’s risk prediction assay outperforms most pathologists in risk stratifying Barrett’s esophagus with low-grade dysplasia
May 2022
Conventional pathology review based on histology has limitations, and the TissueCypher BE risk assessment tool can improve the accuracy of prognosis.
Publication: Podium presentation (695) at DDW 2022, San Diego
An objective fully-automated Barrett's risk prediction assay outperforms most pathologists in risk stratifying Barrett's esophagus with low-grade dysplasia
Apr 2022
Histological review of community-based LGD showed a high inter-observer variability with a signification number of cases classified as non-informative.
Publication: Podium presentation (OP079) at ESGE 2022, Prague
Tissue systems pathology test objectively risk stratifies Barrett’s esophagus patients with low-grade dysplasia
Apr 2021
The risk prediction assay provided significant risk stratification in BE patients with LGD and identified progressors that the experts downstaged to NDBE.
Publication: American Journal of Gastroenterology
The TissueCypher® Barrett’s esophagus assay impacts clinical decisions in the management of patients with Barrett’s esophagus
Mar 2021
The TissueCypher test may enable physicians to target EET for high-risk BE patients, while reducing unnecessary procedures in low-risk patients.
Publication: Endoscopy International Open
Independent validation of a tissue systems pathology assay to predict future progression in non-dysplastic Barrett’s esophagus: a spatial-temporal analysis
Oct 2020
Assessing additional spatial and temporal biopsies increased the predictive accuracy, allowing for identification of most future progressors.
Publication: Clinical and Translational Gastroenterology
Independent blinded validation of a tissue systems pathology test to predict progression in patients with Barrett’s esophagus
Jun 2020
A risk prediction test identifies patients with non-dysplastic Barrett's esophagus who are at high risk for progression to high-grade dysplasia or cancer.
Publication: American Journal of Gastroenterology
Independent validation of TissueCypher to predict future progression in non- dysplastic Barrett’s esophagus: a spatial-temporal analysis
May 2020
An independent validation study showed TissueCypher identified a significant subset of NDBE patients who progress at a rate comparable to expert-confirmed LGD.
Publication: Poster presentation (Sa1189) at DDW 2020, Virtual
Prediction of neoplastic progression in Barrett’s esophagus by pathologic assessment of degree of crypt atypia and by TissueCypher
May 2020
TissueCypher provided superior risk stratification that outperformed crypt atypia scores.
Publication: Poster presentation (Sa1203) at DDW 2020, Virtual
Independent validation of TissueCypher to predict progression in community- based Barrett's esophagus with low-grade dysplasia: analysis in a completed prospective study
May 2020
TissueCypher may be a practical and effective solution to the lack of standardization of expert pathology review if LGD as advocated by all guidelines.
Publication: Podium presentation (1085) at DDW 2020, virtual
Prediction of neoplastic progression in Barrett’s esophagus by pathologic assessment of degree of crypt atypia and by TissueCypher
May 2020
TissueCypher provided superior risk stratification that outperformed crypt atypia scores.
Publication: Poster presentation (Sa1203) at DDW 2020, Virtual
Independent validation of TissueCypher to predict future progression in non- dysplastic Barrett’s esophagus: a spatial-temporal analysis
May 2020
An independent validation study showed TissueCypher identified a significant subset of NDBE patients who progress at a rate comparable to expert-confirmed LGD.
Publication: Poster presentation (Sa1189) at DDW 2020, Virtual
An automated, quantitative multiplex immunofluorescence assay accurately risk stratifies Barrett’s esophagus patients with a community-based diagnosis of low-grade dysplasia at a rate comparable to expert pathologists
Oct 2019
TissueCypher risk stratified BE patients with a community-based diagnosis of LGD with an accuracy comparable to three renowned expert pathologists.
Publication: Poster presentation (372) at ACG 2019, San Antonio